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Abstract The non-enzymatic glycosylation of l~-amyloid is im- 
plicated in the aetiology of Aizheimer's disease. However, contro- 
versy surrounds the nature of any involvement and a potential 
mechanism has not been fully elucidated. We present evidence of 
an aluminium-induced aggregation of the A/3P(25-35) peptide 
and speculate that the mechanism of formation of our ordered 
l~-amyloid aggregates might involve non-enzymatic glycosylation 
and/or site-specific crosslinking of ~-amyloid fibrils by atomic 
aluminium. 
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37 mmol-dm -3Al(NO3)3.9H20 stock (Perkin-Elmer Certified Stock) 
to give a final concentration f 10/zmol. dm 3 total aluminium. Exper- 
imental solutions were maintained at25°C in an incubator for up to 
8 weeks. One hour after the preparation of these solutions and every 
week thereafter for up to 8 weeks each solution was analysed spec- 
trofluorimetrically (Perkin-Elmer LS50) for the formation of Schiff 
bases (an early indicator of glycosylation [8]) and to ascertain the 
biological availability of the added aluminium. The extent of Schiffbase 
formation was shown by emission spectra with maxima in the range 
400-450 nm upon excitation of the solutions at 360 nm. The biological 
availability of the aluminium ineach solution was ascertained upon the 
addition of the fluor Morin (Sigma, UK), excitiation at 420 nm giving 
emission maxima in the wavelength range of 490-510 nm. This method 
is described in full in a paper presently in preparation. 
After 8 weeks, samples from each solution were applied to carbon- 
coated Formvar on 200 mesh copper grids, dried, washed with 2% 
uranyl acetate and viewed in a JEOL 100CX electron microscope. 
1. Introduction 
Recent research as implicated the process of non-enymatic 
glycosylation in the aetiology of Alzheimer's disease (AD) 
[1,2,3]. The research as generated considerable discussion in 
the scientific literature [4,5] as to the role this process might play 
in the formation of neurofibrillary tangles and senile plaques, 
the characteristic pathological structures associated with AD. 
The most recent opinion suggests that the glycosylation of 
fl-amyloid (and tau) occurs only after crosslinking of the pep- 
tide and any subsequent related neuronal damage [5]. The evo- 
lutionary disadvantage of glycosylated protein, such that long- 
lived proteins would not be expected to have exposed glycosyl- 
ation sites [6], could be interpreted to support he latter asser- 
tion. However, if the biochemical environment in the immediate 
vicinity of a protein were to change so as to irreversibly alter 
the conformation of that protein then the susceptibility of the 
protein to non-enzymatic glycosylation could change. We have 
shown that aluminium is an important influence on the confor- 
mations offl-amyloid peptides [7] and in the research detailed 
herein have tested the hypothesis that aluminium would pro- 
mote the non-enzymatic glycosylation of AflP(25 35) by induc- 
ing a conformational change in the peptide structure and thus 
exposing the glycosylation site on the peptide. 
2. Experimental 
Synthetic AflP(25 35) was obtained from Bachem Inc. (CA, USA) 
and dissolved in ultrapure water to give a stock solution of 0.23 
mmol.dm -3. Peptide was then dissolved in NaPIPES buffer 
(Aldrich, UK) at pH 6.0, and containing 5 mmol. dm -3 glucose (Sigma, 
UK), to give a nominal working peptide concentration f 10/zmol. 
dm -3. Aluminium was added to half of these solutions from an acidified 
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3. Results and discussion 
We were not able to identify the occurrence of glycosylation 
in either the presence or absence of aluminium. There were 
increases in the fluorescent signal in both treatments over the 
8 week incubation period and the increase was greater in the 
presence of aluminium than when aluminium was absent. How- 
ever, all of these changes in the fluorescent signal were found 
to be within the 95% confidence intervals. This lack of statisti- 
cal significance does not preclude the possibility that glycosyla- 
tion reactions occurred in either solution as, in hindsight, it is 
possible that our sampling interval was too long (1 week) since 
Schiffbases formed during glycosylation reactions are transient 
forms and may rearrange to give Amadori-like products within 
a few days of their formation [1]. 
The application of Morin as an arbitrary indicator of biolog- 
ical availability revealed an interesting result. We found that the 
influence of the glucose in the solution to which aluminium was 
added was to promote a high and sustained biological availabil- 
ity of aluminium. The biological availability of aluminium was 
increased five-fold compared to several glucose-free control 
solutions. This influence of glucose on the biochemistry of 
aluminium has not hitherto been reported. To ascertain what, 
if any, effect this unusual aluminium chemistry might have on 
the morphology of the fl-amyloid in solution we used electron 
microscopy to look for the formation offl-amyloid fibrils. In 
the absence of added aluminium we observed istinct, relatively 
short, amyloid fibrils of approximately 7-8 nm in diameter (Fig. 
1 a). These single fl-amyloid fibrils were completely absent from 
the solutions containing aluminium and had been replaced by 
aggregates made up of fibrils of approximately 9 10 nm in 
diameter (Fig. lb,c). These structures were considerably onger 
than the single fibrils formed in the absence of aluminium and 
the individual fibrils were spirally wound around each other in 
a paired helical filament-like arrangement. 
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Fig. 1. (a-c) Electron micrographs ofAflP(25-35) in the (a) absence and (b,c) presence of l0 pmol. dm -3 total aluminium. Magnification is 98,000× 
in each plate. 
The aluminium-induced aggregation of the longer fl-amyloid 
peptides [9,10] and the amyloid precursor protein [11] has been 
reported previously. However, in these studies it was neccessary 
to add very high concentrations of aluminium (and sometimes 
peptide) before aggregation of the peptide could be determined. 
Where electron microscopy was undertaken the amyloid was 
found in amorphous aggregates and not in the ordered struc- 
tures found in the research detailed herein. It is possible that 
in these earlier studies amorphous aluminium hydoxide acted 
as a template or seed for the disordered aggregation of the 
peptide, whereas in the present research, the presence of glu- 
cose prevented the formation of such large agglomerates of
aluminium hydroxide and, presented conditions which pro- 
moted the formation of ordered helical structures of,B-amyloid 
either through the promotion of non-enzymatic glycosylation 
or through specific cross-linking reactions i volving atomic 
aluminium. 
In conclusion, whilst non-enzymatic glycosylation might not 
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be expected to be a precursor to the formation of an AD-like 
pathology it is conceivable that small changes in the biological 
environment ofa peptide or protein could implicate this process 
in the aetiology of such a disease state. Strong precedents for 
such already exist in diabetes research [12,13]. 
Acknowledgements: CE is a Royal Society University Research Fellow. 
References 
[1] Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., 
Vlassara, H., Bucala, R., Manogue, K. and Cerami, A. (1994) 
Proc. Natl. Acad. Sci. USA 91, 4766-4770. 
[2] Smith, M.A., Taneda, S., Richey, EL., Miyata, S., Yan, S.-D., 
Stern, D., Sayre, L.M., Monnier, V.M. and Perry, G. (1994) Proc. 
Natl. Acad. Sci. USA 91, 5710-5714. 
[3] Yan, S.-D., Chen, X., Schmidt, A.-M., Brett, J., Godman, G., Zou, 
Y.-S., Scott, C.W., Caputo, C., Frappier, T., Smith, M.A., Perry, 
G., Yen, S.-H. and Stern, D. (1994) Proc. Natl. Acad. Sci. USA 
91, 7787-7791. 
[4] Harrington, C.R. and Colaco, C.A.L.S. (1994) Nature 370, 247- 
248. 
[5] Mattson, M.P., Carney, J.W. and Butterfield, D.A. (1995) Nature 
373, 481. 
[6] Hatton, M.W.C., Richardson, M. and Winocour, ED. (1993) 
J. Theoret. Biol. 161,481-490. 
[7] Exley, C., Price, N.C., Kelly, S.M. and Birchall, J.D. (1993) FEBS 
Lett. 324, 293 295. 
[8] Monnier, V.M. and Cerami, A. (1981) Science 211,491-493. 
[9] Mantyh, P.W., Ghilardi, J.R., Rogers, S., DeMaster, E., Allen, 
C.J., Stimson, E.R. and Maggio, J.E. (1993) J. Neurochem. 61, 
1171 1174. 
[10] Kawahara, M., Muramoto, K., Kobayashi, K., Mori, H. and 
Kuroda, Y. (1994) Biochem. Biophys. Res. Comm. 198, 531- 
535. 
[11] Chong, Y.-H. and Sub, Y.-H. (1995) Brain Res. 670, 137-141. 
[12] Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., 
Cerami, A. and Vlassara, H. (1994) Proc. Natl. Acad. Sci. USA 
91, 9441-9445. 
[13] Yang, C.-W., Vlassara, H., Peten, E.E, He, C.-J., Striker, G.E. 
and Striker, L.J. (1994) Proc. Natl. Acad. Sci. USA 91, 9436- 
9440. 
